APO Research
Talk to an analyst

APO RESEARCH · REPORT

Critical Limb Ischemia Treatment

Critical limb ischemia (CLI) is a severe blockage in the arteries of the lower extremities, which markedly reduces blood-flow. It is a serious form of peripheral arterial disease, or PAD. PAD caused by atherosclerosis, the hardening and narrowing of the arteries over time due to the buildup of fatty deposits called plaque.Currently, the standard of care for patients battling CLI is balloon angioplasty, which relies on a small balloon delivered via a catheter to the blockage to compress it against the arterial wall, opening the vessel and restoring blood flow.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Critical limb ischemia (CLI) is a severe blockage in the arteries of the lower extremities, which markedly reduces blood-flow. It is a serious form of peripheral arterial disease, or PAD. PAD caused by atherosclerosis, the hardening and narrowing of the arteries over time due to the buildup of fatty deposits called plaque.Currently, the standard of care for patients battling CLI is balloon angioplasty, which relies on a small balloon delivered via a catheter to the blockage to compress it against the arterial wall, opening the vessel and restoring blood flow.

Selected research

Market Analysis & Forecast

Global Critical Limb Ischemia Treatment Market Analysis and Forecast 2026-2032

29 December 2025191 pages

Choose your research edition.

Industry ResearchCritical Limb Ischemia Treatment Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Critical Limb Ischemia Treatment Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Critical Limb Ischemia Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Critical Limb Ischemia Treatment Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Critical Limb Ischemia Treatment Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

Critical limb ischemia (CLI) is a severe blockage in the arteries of the lower extremities, which markedly reduces blood-flow. It is a serious form of peripheral arterial disease, or PAD. PAD caused by atherosclerosis, the hardening and narrowing of the arteries over time due to the buildup of fatty deposits called plaque.Currently, the standard of care for patients battling CLI is balloon angioplasty, which relies on a small balloon delivered via a catheter to the blockage to compress it against the arterial wall, opening the vessel and restoring blood flow.

Global critical limb ischemia treatment includes Medtronic, Boston Scientific, Abbott, COOK and Cardiovascular Systems, etc. Global top 3 companies hold a share over 59%. North America is the largest market, with a share about 39%, followed by Europe and Asia-Pacific with the share about 31% and 22%.

Report Includes

Read the full market overview

This report presents an overview of global market for Critical Limb Ischemia Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Critical Limb Ischemia Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Critical Limb Ischemia Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Critical Limb Ischemia Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Critical Limb Ischemia Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Critical Limb Ischemia Treatment revenue, projected growth trends, production technology, application and end-user industry.

Critical Limb Ischemia Treatment Segment by Company

Medtronic

Boston Scientific

Abbott

COOK

Cardiovascular Systems

Terumo

B. Braun

Biotronik

MicroPort Medical

Lepu Medical

Micro Medical Solutions

Critical Limb Ischemia Treatment Segment by Type

Embolic Protection Devices

Peripheral Dilatation Systems

Drugs Treatment

Other

Critical Limb Ischemia Treatment Segment by Application

ASCs

Hospitals

Catheterization Laboratory

Critical Limb Ischemia Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Critical Limb Ischemia Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Critical Limb Ischemia Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Critical Limb Ischemia Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Critical Limb Ischemia Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Critical Limb Ischemia Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Critical Limb Ischemia Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Critical Limb Ischemia Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Embolic Protection Devices Major Player Table 3. Peripheral Dilatation Systems Major Player Table 4. Drugs Treatment Major Player Table 5. Other Major Player Table 6. Global Critical Limb Ischemia Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. ASCs Major Player Table 8. Hospitals Major Player Table 9. Catheterization Laboratory Major Player Table 10. Critical Limb Ischemia Treatment Industry Trends Table 11. Critical Limb Ischemia Treatment Industry Drivers Table 12. Critical Limb Ischemia Treatment Industry Opportunities and Challenges Table 13. Critical Limb Ischemia Treatment Industry Restraints Table 14. Global Critical Limb Ischemia Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Critical Limb Ischemia Treatment Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Critical Limb Ischemia Treatment Market Share by Region (2021-2026) Table 17. Global Critical Limb Ischemia Treatment Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Critical Limb Ischemia Treatment Market Share by Region (2027-2032) Table 19. Global Critical Limb Ischemia Treatment Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Critical Limb Ischemia Treatment Revenue Market Share by Players (2021-2026) Table 21. Global Critical Limb Ischemia Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Critical Limb Ischemia Treatment Key Players Headquarters & Area Served Table 23. Global Critical Limb Ischemia Treatment Players, Product Type & Application Table 24. Global Critical Limb Ischemia Treatment Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Critical Limb Ischemia Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Critical Limb Ischemia Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Critical Limb Ischemia Treatment Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Critical Limb Ischemia Treatment Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Critical Limb Ischemia Treatment Revenue Market Share by Type (2021-2026) Table 31. Global Critical Limb Ischemia Treatment Revenue Market Share by Type (2027-2032) Table 32. Global Critical Limb Ischemia Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Critical Limb Ischemia Treatment Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Critical Limb Ischemia Treatment Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Critical Limb Ischemia Treatment Revenue Market Share by Application (2021-2026) Table 36. Global Critical Limb Ischemia Treatment Revenue Market Share by Application (2027-2032) Table 37. Medtronic Company Information Table 38. Medtronic Business Overview Table 39. Medtronic Critical Limb Ischemia Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Medtronic Critical Limb Ischemia Treatment Product Portfolio Table 41. Medtronic Recent Development Table 42. Boston Scientific Company Information Table 43. Boston Scientific Business Overview Table 44. Boston Scientific Critical Limb Ischemia Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Boston Scientific Critical Limb Ischemia Treatment Product Portfolio Table 46. Boston Scientific Recent Development Table 47. Abbott Company Information Table 48. Abbott Business Overview Table 49. Abbott Critical Limb Ischemia Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Abbott Critical Limb Ischemia Treatment Product Portfolio Table 51. Abbott Recent Development Table 52. COOK Company Information Table 53. COOK Business Overview Table 54. COOK Critical Limb Ischemia Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. COOK Critical Limb Ischemia Treatment Product Portfolio Table 56. COOK Recent Development Table 57. Cardiovascular Systems Company Information Table 58. Cardiovascular Systems Business Overview Table 59. Cardiovascular Systems Critical Limb Ischemia Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Cardiovascular Systems Critical Limb Ischemia Treatment Product Portfolio Table 61. Cardiovascular Systems Recent Development Table 62. Terumo Company Information Table 63. Terumo Business Overview Table 64. Terumo Critical Limb Ischemia Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Terumo Critical Limb Ischemia Treatment Product Portfolio Table 66. Terumo Recent Development Table 67. B. Braun Company Information Table 68. B. Braun Business Overview Table 69. B. Braun Critical Limb Ischemia Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. B. Braun Critical Limb Ischemia Treatment Product Portfolio Table 71. B. Braun Recent Development Table 72. Biotronik Company Information Table 73. Biotronik Business Overview Table 74. Biotronik Critical Limb Ischemia Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Biotronik Critical Limb Ischemia Treatment Product Portfolio Table 76. Biotronik Recent Development Table 77. MicroPort Medical Company Information Table 78. MicroPort Medical Business Overview Table 79. MicroPort Medical Critical Limb Ischemia Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. MicroPort Medical Critical Limb Ischemia Treatment Product Portfolio Table 81. MicroPort Medical Recent Development Table 82. Lepu Medical Company Information Table 83. Lepu Medical Business Overview Table 84. Lepu Medical Critical Limb Ischemia Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Lepu Medical Critical Limb Ischemia Treatment Product Portfolio Table 86. Lepu Medical Recent Development Table 87. Micro Medical Solutions Company Information Table 88. Micro Medical Solutions Business Overview Table 89. Micro Medical Solutions Critical Limb Ischemia Treatment Sales (), Revenue (US$ Million), Price () and Gross Margin (2021-2026) Table 90. Micro Medical Solutions Critical Limb Ischemia Treatment Product Portfolio Table 91. Micro Medical Solutions Recent Development Table 92. North America Critical Limb Ischemia Treatment Revenue by Type (2021-2026) & (US$ Million) Table 93. North America Critical Limb Ischemia Treatment Revenue by Type (2027-2032) & (US$ Million) Table 94. North America Critical Limb Ischemia Treatment Revenue by Application (2021-2026) & (US$ Million) Table 95. North America Critical Limb Ischemia Treatment Revenue by Application (2027-2032) & (US$ Million) Table 96. North America Critical Limb Ischemia Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. North America Critical Limb Ischemia Treatment Revenue by Country (2021-2026) & (US$ Million) Table 98. North America Critical Limb Ischemia Treatment Revenue by Country (US$ Million) & (2027-2032) Table 99. Europe Critical Limb Ischemia Treatment Revenue by Type (2021-2026) & (US$ Million) Table 100. Europe Critical Limb Ischemia Treatment Revenue by Type (2027-2032) & (US$ Million) Table 101. Europe Critical Limb Ischemia Treatment Revenue by Application (2021-2026) & (US$ Million) Table 102. Europe Critical Limb Ischemia Treatment Revenue by Application (2027-2032) & (US$ Million) Table 103. Europe Critical Limb Ischemia Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 104. Europe Critical Limb Ischemia Treatment Revenue by Country (2021-2026) & (US$ Million) Table 105. Europe Critical Limb Ischemia Treatment Revenue by Country (US$ Million) & (2027-2032) Table 106. China Critical Limb Ischemia Treatment Revenue by Type (2021-2026) & (US$ Million) Table 107. China Critical Limb Ischemia Treatment Revenue by Type (2027-2032) & (US$ Million) Table 108. China Critical Limb Ischemia Treatment Revenue by Application (2021-2026) & (US$ Million) Table 109. China Critical Limb Ischemia Treatment Revenue by Application (2027-2032) & (US$ Million) Table 110. Asia Critical Limb Ischemia Treatment Revenue by Type (2021-2026) & (US$ Million) Table 111. Asia Critical Limb Ischemia Treatment Revenue by Type (2027-2032) & (US$ Million) Table 112. Asia Critical Limb Ischemia Treatment Revenue by Application (2021-2026) & (US$ Million) Table 113. Asia Critical Limb Ischemia Treatment Revenue by Application (2027-2032) & (US$ Million) Table 114. Asia Critical Limb Ischemia Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 115. Asia Critical Limb Ischemia Treatment Revenue by Region (US$ Million) & (2021-2026) Table 116. Asia Critical Limb Ischemia Treatment Revenue by Region (US$ Million) & (2027-2032) Table 117. SAMEA Critical Limb Ischemia Treatment Revenue by Type (2021-2026) & (US$ Million) Table 118. SAMEA Critical Limb Ischemia Treatment Revenue by Type (2027-2032) & (US$ Million) Table 119. SAMEA Critical Limb Ischemia Treatment Revenue by Application (2021-2026) & (US$ Million) Table 120. SAMEA Critical Limb Ischemia Treatment Revenue by Application (2027-2032) & (US$ Million) Table 121. SAMEA Critical Limb Ischemia Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 122. SAMEA Critical Limb Ischemia Treatment Revenue by Country (2021-2026) & (US$ Million) Table 123. SAMEA Critical Limb Ischemia Treatment Revenue by Country (US$ Million) & (2027-2032) Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. Critical Limb Ischemia Treatment Image Figure 2. Global Critical Limb Ischemia Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Critical Limb Ischemia Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Embolic Protection Devices Image Figure 5. Peripheral Dilatation Systems Image Figure 6. Drugs Treatment Image Figure 7. Other Image Figure 8. Global Critical Limb Ischemia Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Critical Limb Ischemia Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 10. ASCs Image Figure 11. Hospitals Image Figure 12. Catheterization Laboratory Image Figure 13. Global Critical Limb Ischemia Treatment Market Size (US$ Million) & (2021-2032) Figure 14. Global Critical Limb Ischemia Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Critical Limb Ischemia Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Critical Limb Ischemia Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Critical Limb Ischemia Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Critical Limb Ischemia Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Critical Limb Ischemia Treatment Revenue Market Share by Type (2021-2032) Figure 21. Global Critical Limb Ischemia Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Critical Limb Ischemia Treatment Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Critical Limb Ischemia Treatment Revenue Market Share by Application (2021-2032) Figure 24. North America Critical Limb Ischemia Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Critical Limb Ischemia Treatment Revenue Share by Type (2021-2032) Figure 26. North America Critical Limb Ischemia Treatment Revenue Share by Application (2021-2032) Figure 27. North America Critical Limb Ischemia Treatment Revenue Share by Country (2021-2032) Figure 28. United States Critical Limb Ischemia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Critical Limb Ischemia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Critical Limb Ischemia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Critical Limb Ischemia Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Critical Limb Ischemia Treatment Revenue Share by Type (2021-2032) Figure 33. Europe Critical Limb Ischemia Treatment Revenue Share by Application (2021-2032) Figure 34. Europe Critical Limb Ischemia Treatment Revenue Share by Country (2021-2032) Figure 35. Germany Critical Limb Ischemia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Critical Limb Ischemia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Critical Limb Ischemia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Critical Limb Ischemia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Critical Limb Ischemia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Critical Limb Ischemia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Critical Limb Ischemia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Critical Limb Ischemia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Critical Limb Ischemia Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Critical Limb Ischemia Treatment Revenue Share by Type (2021-2032) Figure 45. China Critical Limb Ischemia Treatment Revenue Share by Application (2021-2032) Figure 46. Asia Critical Limb Ischemia Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Critical Limb Ischemia Treatment Revenue Share by Type (2021-2032) Figure 48. Asia Critical Limb Ischemia Treatment Revenue Share by Application (2021-2032) Figure 49. Asia Critical Limb Ischemia Treatment Revenue Share by Region (2021-2032) Figure 50. Japan Critical Limb Ischemia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Critical Limb Ischemia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Critical Limb Ischemia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Critical Limb Ischemia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Critical Limb Ischemia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Critical Limb Ischemia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Critical Limb Ischemia Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Critical Limb Ischemia Treatment Revenue Share by Type (2021-2032) Figure 58. SAMEA Critical Limb Ischemia Treatment Revenue Share by Application (2021-2032) Figure 59. SAMEA Critical Limb Ischemia Treatment Revenue Share by Country (2021-2032) Figure 60. Brazil Critical Limb Ischemia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Critical Limb Ischemia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Critical Limb Ischemia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Critical Limb Ischemia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Critical Limb Ischemia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Critical Limb Ischemia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Critical Limb Ischemia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Critical Limb Ischemia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Critical Limb Ischemia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Critical Limb Ischemia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Critical Limb Ischemia Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Embolic Protection Devices
  • Peripheral Dilatation Systems
  • Drugs Treatment
  • Other
Applications
  • ASCs
  • Hospitals
  • Catheterization Laboratory
Companies covered
  • Medtronic
  • Boston Scientific
  • Abbott
  • COOK
  • Cardiovascular Systems
  • Terumo
  • B. Braun
  • Biotronik
  • MicroPort Medical
  • Lepu Medical
  • Micro Medical Solutions

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Critical Limb Ischemia Treatment Market by Type
  3. 1.2.1 Global Critical Limb Ischemia Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Embolic Protection Devices
  5. 1.2.3 Peripheral Dilatation Systems
  6. 1.2.4 Drugs Treatment
  7. 1.2.5 Other
  8. 1.3 Critical Limb Ischemia Treatment Market by Application
  9. 1.3.1 Global Critical Limb Ischemia Treatment Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 ASCs
  11. 1.3.3 Hospitals
  12. 1.3.4 Catheterization Laboratory
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Critical Limb Ischemia Treatment Market Dynamics
  1. 2.1 Critical Limb Ischemia Treatment Industry Trends
  2. 2.2 Critical Limb Ischemia Treatment Industry Drivers
  3. 2.3 Critical Limb Ischemia Treatment Industry Opportunities and Challenges
  4. 2.4 Critical Limb Ischemia Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Critical Limb Ischemia Treatment Market Perspective (2021-2032)
  2. 3.2 Global Critical Limb Ischemia Treatment Growth Trends by Region
  3. 3.2.1 Global Critical Limb Ischemia Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Critical Limb Ischemia Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global Critical Limb Ischemia Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Critical Limb Ischemia Treatment Revenue by Players
  2. 4.1.1 Global Critical Limb Ischemia Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global Critical Limb Ischemia Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Critical Limb Ischemia Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Critical Limb Ischemia Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Critical Limb Ischemia Treatment Key Players Headquarters & Area Served
  7. 4.4 Global Critical Limb Ischemia Treatment Players, Product Type & Application
  8. 4.5 Global Critical Limb Ischemia Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Critical Limb Ischemia Treatment Market CR5 and HHI
  11. 4.6.3 2025 Critical Limb Ischemia Treatment Tier 1, Tier 2, and Tier 3
5 Critical Limb Ischemia Treatment Market Size by Type
  1. 5.1 Global Critical Limb Ischemia Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Critical Limb Ischemia Treatment Revenue by Type (2021-2032)
  3. 5.3 Global Critical Limb Ischemia Treatment Revenue Market Share by Type (2021-2032)
6 Critical Limb Ischemia Treatment Market Size by Application
  1. 6.1 Global Critical Limb Ischemia Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Critical Limb Ischemia Treatment Revenue by Application (2021-2032)
  3. 6.3 Global Critical Limb Ischemia Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Medtronic
  2. 7.1.1 Medtronic Company Information
  3. 7.1.2 Medtronic Business Overview
  4. 7.1.3 Medtronic Critical Limb Ischemia Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Medtronic Critical Limb Ischemia Treatment Product Portfolio
  6. 7.1.5 Medtronic Recent Developments
  7. 7.2 Boston Scientific
  8. 7.2.1 Boston Scientific Company Information
  9. 7.2.2 Boston Scientific Business Overview
  10. 7.2.3 Boston Scientific Critical Limb Ischemia Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Boston Scientific Critical Limb Ischemia Treatment Product Portfolio
  12. 7.2.5 Boston Scientific Recent Developments
  13. 7.3 Abbott
  14. 7.3.1 Abbott Company Information
  15. 7.3.2 Abbott Business Overview
  16. 7.3.3 Abbott Critical Limb Ischemia Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Abbott Critical Limb Ischemia Treatment Product Portfolio
  18. 7.3.5 Abbott Recent Developments
  19. 7.4 COOK
  20. 7.4.1 COOK Company Information
  21. 7.4.2 COOK Business Overview
  22. 7.4.3 COOK Critical Limb Ischemia Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 COOK Critical Limb Ischemia Treatment Product Portfolio
  24. 7.4.5 COOK Recent Developments
  25. 7.5 Cardiovascular Systems
  26. 7.5.1 Cardiovascular Systems Company Information
  27. 7.5.2 Cardiovascular Systems Business Overview
  28. 7.5.3 Cardiovascular Systems Critical Limb Ischemia Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Cardiovascular Systems Critical Limb Ischemia Treatment Product Portfolio
  30. 7.5.5 Cardiovascular Systems Recent Developments
  31. 7.6 Terumo
  32. 7.6.1 Terumo Company Information
  33. 7.6.2 Terumo Business Overview
  34. 7.6.3 Terumo Critical Limb Ischemia Treatment Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Terumo Critical Limb Ischemia Treatment Product Portfolio
  36. 7.6.5 Terumo Recent Developments
  37. 7.7 B. Braun
  38. 7.7.1 B. Braun Company Information
  39. 7.7.2 B. Braun Business Overview
  40. 7.7.3 B. Braun Critical Limb Ischemia Treatment Revenue and Gross Margin (2021-2026)
  41. 7.7.4 B. Braun Critical Limb Ischemia Treatment Product Portfolio
  42. 7.7.5 B. Braun Recent Developments
  43. 7.8 Biotronik
  44. 7.8.1 Biotronik Company Information
  45. 7.8.2 Biotronik Business Overview
  46. 7.8.3 Biotronik Critical Limb Ischemia Treatment Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Biotronik Critical Limb Ischemia Treatment Product Portfolio
  48. 7.8.5 Biotronik Recent Developments
  49. 7.9 MicroPort Medical
  50. 7.9.1 MicroPort Medical Company Information
  51. 7.9.2 MicroPort Medical Business Overview
  52. 7.9.3 MicroPort Medical Critical Limb Ischemia Treatment Revenue and Gross Margin (2021-2026)
  53. 7.9.4 MicroPort Medical Critical Limb Ischemia Treatment Product Portfolio
  54. 7.9.5 MicroPort Medical Recent Developments
  55. 7.10 Lepu Medical
  56. 7.10.1 Lepu Medical Company Information
  57. 7.10.2 Lepu Medical Business Overview
  58. 7.10.3 Lepu Medical Critical Limb Ischemia Treatment Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Lepu Medical Critical Limb Ischemia Treatment Product Portfolio
  60. 7.10.5 Lepu Medical Recent Developments
  61. 7.11 Micro Medical Solutions
  62. 7.11.1 Micro Medical Solutions Company Information
  63. 7.11.2 Micro Medical Solutions Business Overview
  64. 7.11.3 Micro Medical Solutions Critical Limb Ischemia Treatment Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Micro Medical Solutions Critical Limb Ischemia Treatment Product Portfolio
  66. 7.11.5 Micro Medical Solutions Recent Developments
8 North America
  1. 8.1 North America Critical Limb Ischemia Treatment Revenue (2021-2032)
  2. 8.2 North America Critical Limb Ischemia Treatment Revenue by Type (2021-2032)
  3. 8.2.1 North America Critical Limb Ischemia Treatment Revenue by Type (2021-2026)
  4. 8.2.2 North America Critical Limb Ischemia Treatment Revenue by Type (2027-2032)
  5. 8.3 North America Critical Limb Ischemia Treatment Revenue Share by Type (2021-2032)
  6. 8.4 North America Critical Limb Ischemia Treatment Revenue by Application (2021-2032)
  7. 8.4.1 North America Critical Limb Ischemia Treatment Revenue by Application (2021-2026)
  8. 8.4.2 North America Critical Limb Ischemia Treatment Revenue by Application (2027-2032)
  9. 8.5 North America Critical Limb Ischemia Treatment Revenue Share by Application (2021-2032)
  10. 8.6 North America Critical Limb Ischemia Treatment Revenue by Country
  11. 8.6.1 North America Critical Limb Ischemia Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Critical Limb Ischemia Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America Critical Limb Ischemia Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Critical Limb Ischemia Treatment Revenue (2021-2032)
  2. 9.2 Europe Critical Limb Ischemia Treatment Revenue by Type (2021-2032)
  3. 9.2.1 Europe Critical Limb Ischemia Treatment Revenue by Type (2021-2026)
  4. 9.2.2 Europe Critical Limb Ischemia Treatment Revenue by Type (2027-2032)
  5. 9.3 Europe Critical Limb Ischemia Treatment Revenue Share by Type (2021-2032)
  6. 9.4 Europe Critical Limb Ischemia Treatment Revenue by Application (2021-2032)
  7. 9.4.1 Europe Critical Limb Ischemia Treatment Revenue by Application (2021-2026)
  8. 9.4.2 Europe Critical Limb Ischemia Treatment Revenue by Application (2027-2032)
  9. 9.5 Europe Critical Limb Ischemia Treatment Revenue Share by Application (2021-2032)
  10. 9.6 Europe Critical Limb Ischemia Treatment Revenue by Country
  11. 9.6.1 Europe Critical Limb Ischemia Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Critical Limb Ischemia Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe Critical Limb Ischemia Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Critical Limb Ischemia Treatment Revenue (2021-2032)
  2. 10.2 China Critical Limb Ischemia Treatment Revenue by Type (2021-2032)
  3. 10.2.1 China Critical Limb Ischemia Treatment Revenue by Type (2021-2026)
  4. 10.2.2 China Critical Limb Ischemia Treatment Revenue by Type (2027-2032)
  5. 10.3 China Critical Limb Ischemia Treatment Revenue Share by Type (2021-2032)
  6. 10.4 China Critical Limb Ischemia Treatment Revenue by Application (2021-2032)
  7. 10.4.1 China Critical Limb Ischemia Treatment Revenue by Application (2021-2026)
  8. 10.4.2 China Critical Limb Ischemia Treatment Revenue by Application (2027-2032)
  9. 10.5 China Critical Limb Ischemia Treatment Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Critical Limb Ischemia Treatment Revenue (2021-2032)
  2. 11.2 Asia Critical Limb Ischemia Treatment Revenue by Type (2021-2032)
  3. 11.2.1 Asia Critical Limb Ischemia Treatment Revenue by Type (2021-2026)
  4. 11.2.2 Asia Critical Limb Ischemia Treatment Revenue by Type (2027-2032)
  5. 11.3 Asia Critical Limb Ischemia Treatment Revenue Share by Type (2021-2032)
  6. 11.4 Asia Critical Limb Ischemia Treatment Revenue by Application (2021-2032)
  7. 11.4.1 Asia Critical Limb Ischemia Treatment Revenue by Application (2021-2026)
  8. 11.4.2 Asia Critical Limb Ischemia Treatment Revenue by Application (2027-2032)
  9. 11.5 Asia Critical Limb Ischemia Treatment Revenue Share by Application (2021-2032)
  10. 11.6 Asia Critical Limb Ischemia Treatment Revenue by Country
  11. 11.6.1 Asia Critical Limb Ischemia Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Critical Limb Ischemia Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia Critical Limb Ischemia Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Critical Limb Ischemia Treatment Revenue (2021-2032)
  2. 12.2 SAMEA Critical Limb Ischemia Treatment Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Critical Limb Ischemia Treatment Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Critical Limb Ischemia Treatment Revenue by Type (2027-2032)
  5. 12.3 SAMEA Critical Limb Ischemia Treatment Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Critical Limb Ischemia Treatment Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Critical Limb Ischemia Treatment Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Critical Limb Ischemia Treatment Revenue by Application (2027-2032)
  9. 12.5 SAMEA Critical Limb Ischemia Treatment Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Critical Limb Ischemia Treatment Revenue by Country
  11. 12.6.1 SAMEA Critical Limb Ischemia Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Critical Limb Ischemia Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Critical Limb Ischemia Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst